Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
about
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective StudyAtherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings.Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapyPlasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations.Depolarization of mitochondrial membrane potential is the initial event in non-nucleoside reverse transcriptase inhibitor efavirenz induced cytotoxicity.Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial.Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.Lipid Changes in Virologically Suppressed HIV-Infected Patients Switching from any Antiretroviral Therapy to the Emtricitabine/Rilpivirine/Tenofovir Single Tablet: GeSida Study 8114.The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.Changes in plasma lipidome following initiation of antiretroviral therapy
P2860
Q28554630-A9E2FCEA-462B-4BC2-9D96-8F6AC04BA8A4Q30248286-2DA990BE-A438-454F-9082-4CC6508BA5C3Q33644568-0A8A3CBC-1475-4C95-A17A-74E45B82A468Q35567828-5EC285F1-3050-4B69-9A6F-0AA7ECFE222EQ35628276-06D97316-FE97-4AFA-8DDA-D0553AB5D6A8Q36436780-E9A90875-8DAA-4593-881D-82099DC47502Q36478066-EDB0E2E0-6AC2-4BF5-B34E-157993E648B0Q40577108-1A51BDE9-2A2F-4C35-AFB7-30D3AFED8372Q40751471-03014E3B-AE9F-421D-BBBF-EF90A98C5499Q40790663-AB7E649C-FBA8-4D0A-9DC5-D598E0AA3E32Q40799305-2C0D74D7-24C5-483E-AD76-FD803D00F3D8Q41546697-33CC54D0-D33D-452C-9743-476D429F2FB1Q57167016-CE1DF5D7-C8CF-4050-92F3-12169B494705
P2860
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Lipid levels and changes in bo ...... in the ECHO and THRIVE trials.
@en
Lipid levels and changes in bo ...... in the ECHO and THRIVE trials.
@nl
type
label
Lipid levels and changes in bo ...... in the ECHO and THRIVE trials.
@en
Lipid levels and changes in bo ...... in the ECHO and THRIVE trials.
@nl
prefLabel
Lipid levels and changes in bo ...... in the ECHO and THRIVE trials.
@en
Lipid levels and changes in bo ...... in the ECHO and THRIVE trials.
@nl
P2093
P2860
P50
P356
P1476
Lipid levels and changes in bo ...... in the ECHO and THRIVE trials.
@en
P2093
Dan Duiculescu
ECHO and THRIVE Study Groups
Henri Deckx
Marita Stevens
Michael Sension
Simon Vanveggel
Timothy Wilkin
P2860
P304
P356
10.1093/CID/CIU234
P407
P577
2014-04-11T00:00:00Z